NCT04021862 – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis Posted on August 5, 2023 by tsuperadmin -
NCT00317538 – Open-label, Pilot Protocol of Patients with Rheumatoid Arthritis Who Switch to Infliximab after Incomplete Response to Etanercept Posted on August 5, 2023 by tsuperadmin -
NCT00816166 – Phase III Study of Pharos Vitesse Neurovascular Stent System Compared to Best Medical Therapy for the Treatment of Ischemic Disease Posted on August 5, 2023 by tsuperadmin -
NCT02165397 – iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström’s Macroglobulinemia Posted on August 5, 2023 by tsuperadmin -
NCT02382016 – A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension Posted on August 5, 2023 by tsuperadmin -
NCT00207727 – A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis Posted on August 5, 2023 by tsuperadmin -
NCT01946204 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer Posted on August 5, 2023 by tsuperadmin -
NCT03277105 – A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Posted on August 5, 2023 by tsuperadmin -
NCT03412565 – A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens Posted on August 5, 2023 by tsuperadmin -
NCT01998971 – An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma Posted on August 5, 2023 by tsuperadmin -
The YODA Project